Biotech M&A premium compression - sector desperation?

Pfizer just paid 12x revenue for Seagen while today's deals are barely hitting 3x. Either we're seeing rational pricing finally or this whole sector is more distressed than the headlines suggest.

The biotech premium compression is screaming distress - when you're seeing 75% haircuts on acquisition multiples in 18 months, that's not rational repricing, that's forced selling by overleveraged buyers. My base case is we get another 6 months of brutal M&A comps before the sector finds a floor.

The way I'm thinking about this biotech M&A collapse - when Pfizer can only get 3x revenue for assets that would've commanded 12x two years ago, that's telling you the entire sector is in capital preservation mode. I'm seeing this in my small biotech positions too - companies with decent pipelines trading at cash value because nobody believes in the financing environment anymore.

The brutal part is when you look at the quality of assets getting fire-saled - some of these biotechs have Phase 3 programs that would've been billion-dollar takeouts in 2021, now trading below cash because the acquirer base just evaporated. Big pharma balance sheets are stretched and PE can't get financing.

The financing drought is the real story here - when biotech debt markets are essentially closed and equity raises are getting done at 50% discounts to market, you're looking at a classic liquidity-driven selloff that creates the M&A fire sales. Big pharma knows they can wait another quarter and get even better deals.

The thing that's killing me is watching my XBI position - these companies are burning cash with 18-month runways while their potential acquirers are sitting on their hands waiting for even cheaper deals. When you've got quality assets trading at 0.5x book because financing markets are dead, that's not a buying opportunity yet, that's a falling knife.

The credit crunch is forcing biotech into a classic balance sheet recession - when your sector ETF is down 60% from peaks and nobody can access debt markets, M&A becomes the only liquidity valve. Big pharma's playing the waiting game because they know desperation selling has another 6 months to run.